M Ventures, Novartis Venture Fund and Pfizer Ventures are among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

UK-based cancer therapy developer Artios Pharma secured $153m in a series C round on Tuesday from investors including pharmaceutical firms Merck Group, Novartis and Pfizer.

Investment firms Omega Funds and TCG Crossover co-led the round, which included Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management and Schroders Capital.

Returning backers Arix Bioscience, SV Health Investors, Andera Partners, LSP (Life Sciences Partners) and IP Group also took…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn